Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Mr. Cohen is a Managing Director at RBC Capital Markets, where he is responsible for Healthcare Mergers & Acquisitions and the firm’s relationships with pharmaceutical and medical device outsourcing companies including CMOs. He is an accomplished M&A practitioner, having worked with and advised companies over almost 20 years on the execution of M&A transactions valued at over $75 billion. Prior to joining RBC in 2015, he was a member of the Executive Leadership Team and head of Corporate Development at Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products and a Blackstone portfolio company which completed its IPO in July 2014. He joined Catalent in 2010 and, after developing and initiating Catalent’s inorganic strategy, completed 14 transactions valued at approximately $1 billion.
Mr. Cohen’s transaction experience at Catalent included acquisitions (Aptuit CTS, Micron Technologies, 49% interest in RP Scherer Eberbach), divestitures (Catalent’s Printed Components and North American Packaging businesses), structured transactions (Redwood Bioscience minority stake/call option/buyout) and emerging markets (two China JVs and acquisition of Relthy Laboratorios in Brazil). He has extensive experience evaluating the acquisition and monetization of pharmaceutical products, having completed multiple transactions including the acquisition of US rights to propranolol ER from Forest Laboratories.
Prior to Catalent, Mr. Cohen spent 13 years on Wall Street where he focused on healthcare M&A, particularly within the drug delivery, specialty pharma and generic pharma industries, including at JP Morgan and Bear Stearns.